HER2 (Phospho_Tyr877) Antibody
- Known as:
- HER2 (Phospho_Tyr877) Antibody
- Catalog number:
- E011075-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- HER2 (Phospho_Tyr877) Antibody
Related genes to: HER2 (Phospho_Tyr877) Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 (Phospho_Tyr877) Antibody
Related articles to: HER2 (Phospho_Tyr877) Antibody
- - Source: PubMed
Publication date: 2026/04/23
Timms John FWhite Sarah LO'Hare Michael JWaterfield Michael D - HER2-positive breast cancer, characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), accounts for approximately 15-20% of all breast cancers and is associated with aggressive tumor behavior and poor prognosis. Advances in HER2-targeted therapies, such as monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs), have significantly improved treatment outcomes in this subtype. Neoadjuvant therapy, administered before surgery, has become a cornerstone in managing HER2-positive breast cancer by improving pathological complete response (pCR) rates and survival outcomes. This review provides a comprehensive analysis of recent advancements in HER2-targeted neoadjuvant therapies, highlighting the mechanisms of action, clinical efficacy, and synergistic effects when combined with chemotherapy. Key challenges, such as treatment-related toxicities, and the potential for personalized treatment strategies based on biomarkers like tumor-infiltrating lymphocytes (TILs) and HER2-enriched subtypes, are discussed. Future directions emphasize optimizing treatment regimens to enhance efficacy while minimizing adverse effects, with novel agents such as trastuzumab deruxtecan (T-DXd) showing promise for expanding the therapeutic landscape. - Source: PubMed
Publication date: 2026/04/22
Shang AnqiXiong YunjingLi MinTang WanxinWan KeyuDeng ZekangMao XianxianChen Haizhu - Comorbidities, common in patients with advanced breast cancer (ABC), may impact survival outcomes and health-related quality of life (HRQoL). Here, we report subgroup analyses on the basis of comorbidities of patients from POLARIS (NCT03280303), a prospective, observational study of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) ABC who were treated with palbociclib plus endocrine therapy in routine clinical practice in North America. - Source: PubMed
Tripathy DebuBlum Joanne LKaruturi Meghan SMcCune StevenKurian SobhaMoezi Mehdi MAnderson Daniel MJi YanPluard Timothy JMigas JohnLakhanpal ShailendraJepsen ErinWang YaoMontelongo Monica ZZhang ZheCappelleri Joseph CGauthier EricRocque Gabrielle B - To evaluate the frequency of molecular subtypes of breast carcinoma, and to determine their association with clinicopathological parameters. - Source: PubMed
Khaliq ErumShawana Summayya - EMP3 is closely associated with HER2 expression and trastuzumab resistance. However, the prognostic value of EMP3 in the HER2 subtype remains poorly understood. It is necessary to clarify the relationship between EMP3 and prognosis in HER2-enriched breast cancer. - Source: PubMed
Zhu MingdaTian ChenyangNkenfag Ninine MartheWang NiannianYu Weiping